HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.

By Stefanie Dimmeler, Alexandra Aicher, M. Vasa, Christiane Mildner-Rihm, K. Adler, M. Tiemann, H. Rütten, S. Fichtlscherer, H. Martin, A. Zeiher. Journal of Clinical Investigation, 2001

1,257 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/04c117082dc2a14d252c35810610e6a8aadd2548

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Lyden

In Hematology

1. D. Lyden

In Molecular Biology

1. Stefanie Dimmeler
2. A. Zeiher
3. C. Urbich
4. D. Lyden
5. C. Heeschen
6. Alexandra Aicher
7. Shahin Rafii
8. J. Liao

Citations in the corpus

• Pleiotropic effects of statins. (2005, background): “STATINS AND ENDOTHELIAL PROGENITOR CELLS Statins have also been found to increase the number of circulating endothelial progenitor cells (EPCs) (69).”
• Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization (2002, background): “Recently, it was demonstrated that hydroxymethylglutaryl (HMG)-CoA reductase inhibitors potently augment EPC differentiation by a mechanism involving the angiogenic protein kinase Akt (ref”
• Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration (2003, background): “Remarkably, 3-hydroxyl-3-methyl coenzyme A reductase inhibitors (statins) promote incorporation of EPCs into neoangiogenic site”
• Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. (2005, background): “These endothelial progenitor cells are positive for endothelial marker proteins such as VEGF receptor 2 (KDR), von Willebrand factor (vWF), VE-cadherin, eNOS, take-up of diacetylated LDL, and bind lectin [5–7].”